However, drugs targeting PI3K/Akt/mTOR pathway showed promising results in preclinical models of B-ALL, through the direct inhibition of tumor cell growth and by reversal of GC resistance, although with a limited success when used as single anticancer agents [106]. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.